Trimel to Present at the Upcoming Investor Conferences

(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 08/30/12 -- Trimel Pharmaceuticals Corporation (TSX: TRL) (the "Company" or "Trimel") today announced that it will participate in the Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons Hotel in Boston, MA on September 6th, 2012 at 4:25pm EDT and the Rodman and Renshaw 14th Annual Global Investment Conference at the Waldorf Astoria Hotel in New York, NY on September 10th, 2012 at 2:25pm EDT.

Mr. Kenneth Howling, Chief Financial Officer, is scheduled to present an overview of the Company at the upcoming conferences. The presentation materials will also be available on the Trimel website at .

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at .

About Trimel

Trimel Pharmaceuticals Corporation (TSX: TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit .



Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 30.08.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 179071
Anzahl Zeichen: 0

contact information:
Town:

TORONTO, ONTARIO

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 193 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Trimel to Present at the Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von

Trimel Pharmaceuticals Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Trimel Announces Filing of NATESTO(TM) With Health Canada ...

TORONTO, ONTARIO -- (Marketwired) -- 01/26/15 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that it has filed a New Drug Submission with Health Canada for NATESTO™ (testosterone) nasal gel for replacement therapy in men for cond ...

Trimel Announces Closing of Exclusive Agreement for NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 12/09/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International ...

Trimel Announces Issuance of Additional Patent Covering NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 11/25/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO™ and its propri ...

Alle Meldungen von Trimel Pharmaceuticals Corporation